Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

This study has been completed.
Sponsor:
Collaborators:
Aventis Pharmaceuticals
Millennium Pharmaceuticals, Inc.
Information provided by:
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT00193232
First received: September 12, 2005
Last updated: July 27, 2010
Last verified: July 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2007
  Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Publications: